Celgene (CELG): Relevance Fails, PT Drops To $147 - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Celgene (CELG) PT Lowered to $130 at Stifel; 'Revlimid Plus Ritxuan did not Achieve Superiority with Co-Primary Endpoints'
December 22, 2017 8:18 AM ESTStifel lowered its price target on Celgene (NASDAQ: CELG) to $130.00 (from $149.00) while maintaining a Buy rating, following the company's announcement regarding an update of Phase 3 trial Revlimid (Revevance).
Analyst Thomas Shrader notes a cautious outlook on the shares, commenting "that Phase III trial... More
